Hanmi, “Olmutinib in progress, Phase 3 plan temporarily suspended”
When it comes to the ‘the300’s(Money Today)’ article ‘Boehringer already suspended clinical trial this August… did it really not know about it,’ Hanmi Pharm announced on the 7th that the Phase 2 clinical trial was in progress at the time when the letters mentioned in the article was exchanged, an...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
